Pancreatic cancer ascites xenograft-an expeditious model mirroring advanced therapeutic resistant disease.

导出 OA

翻译打印收藏纠错

作者： Talia,Golan ^[1] ; Chani,Stossel ^[2] ; Michael,Schvimer ^[1] ; Dikla,Atias ^[3] ; Sharon,Halperin ^[1] ; Ella,Buzhor ^[1] ; Maria,Raitses-Gurevich ^[1] ; Keren,Cohen ^[1] ; Sara,Pri-Chen ^[1] ; Julie,Wilson ^[4] ; Robert E,Denroche ^[5] ; Ilinca,Lungu ^[6] ; John M S,Bartlett ^[6] ; Faridah,Mbabaali ^[5] ; Yosef,Yarden ^[5] ; Nishanth Belugali,Nataraj ^[7] ; Steven,Gallinger ^[7] ; Raanan,Berger ^[5]

作者单位： Pancreatic Cancer Translational Research Laboratory, Oncology Institute, Sheba Medical Center, Tel Hashomer, Israel. ^[1] Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. ^[2] Pathology Department, Sheba Medical Center, Tel Hashomer, Israel. ^[3] Microsurgery Laboratory, Eye Institute, Sheba Medical Center, Tel Hashomer, Israel. ^[4] Ontario Institute for Cancer Research, Toronto, Canada. ^[5] Department of Surgery, University Health Network, Toronto, Canada. ^[6] Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel. ^[7] Oncology Institute, Sheba Medical Center, Tel Hashomer, Israel. ^[8]

关键词 ascites metastatic pancreatic ductal adenocarcinoma (PDAC)patient derived xenograft (PDX)whole genome sequencing (WGS)